Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Aptamers Market Size Worth USD 925 million by 2035 | Roots Analysis

This image opens in the lightbox

News provided by

Roots Analysis

11 Dec, 2023, 15:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Dec. 11, 2023 /PRNewswire/ -- According to the recently published report by Roots Analysis, the increasing awareness of aptamers-based therapeutics in targeting a wide range of indications such as metabolic disorders is driving the aptamer market.

Global Aptamers Market Overview

The global aptamers market size was estimated to be USD 30 million in 2023 and is expected to reach USD 925 million by 2035, growing at a compounded annual growth rate of 33% during the forecast period 2024-2035.

Aptamers refer to the single-stranded DNA and RNA molecules that have the potential to bind to a particular target selectively. These molecules are useful in characterizing and inhibiting proteins and can be re-engineered to enhance affinity and higher specificity. Owing to the binding efficiency, pharmaceutical players use aptamers to produce aptamers-based therapeutics targeting a wide range of therapeutic areas, such as metabolic, oncological, and ophthalmological disorders. It is interesting to note that several companies are accelerating research efforts to understand the therapeutic usage of aptamers. Driven by ongoing research and rising awareness about their advantages, the aptamers market is anticipated to grow at a steady rate during the forecast period.

At present, such technologies are widely being used for pathogen recognition, cancer recognition, monitoring environmental contamination, and as stem cell markers, which can help in both disease prevention and treatment. In addition, post the onset of COVID-19 pandemic, there has been a significant rise in the demand for COVID-19 testing kits, which has prompted several companies to develop aptamer-based diagnostic tools for the detection of SARS-CoV-2. Consequently, to support the various initiatives undertaken by industry players, investments worth over USD 1.3 billion have been reported in the past five years.

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/aptamers-therapeutics-technologies-and-services-market/request-sample.html

Market Drivers

The rising awareness of benefits of aptamers over antibodies is driving the aptamers market. Aptamers have the potential to bind to small molecules that can be used in conventional disease diagnostic kits, enhancing the utilization of aptamers for point-of-care diagnostics. Furthermore, the increasing demand for aptamers-based portable diagnostic devices due to higher accuracy levels drives the market during the forecast period.

Market Restraints

Several market restraints that restrict the aptamer market growth are low affinity and acceptance by the pharmaceuticals. Though aptamers have shown efficiency in targeting a wide range of molecules, several studies have shown that the oligonucleotide structure of aptamers may restrict interaction between targeted molecules and aptamers. Moreover, aptamer targets are present in blood plasma, so they are easily accessible from blood cells━leading to exposure of aptamers to nuclease degradation, renal filtration, liver, and spleen. This became the paramount reason for the pharmaceutical players' low acceptance of the market.

Growth Factors 

Several aptamers market players are investing increasingly in exploring the potential applications of aptamers for diagnostic and therapeutic purposes. Most players now emphasize securing funding to strengthen their research and capabilities to manufacture aptamers. Additionally, aptamers are potent for therapeutic applications in various diseases, such as cardiovascular disorders, metabolic disorders, and neurodegenerative disorders. The aptamers market will grow in the upcoming years, driven by ongoing study and raising funding activities.

Aptamers Market Segments

Based on the type of aptamers, the aptamers market is segmented into DNA, RNA, and L-RNA.

  • RNA aptamer segment drives the aptamers industry, capturing 50.4%% revenue share by 2035.
  • The L-RNA segment is anticipated to grow at a steady rate, holding 45% share by 2035.

Based on target indication, the aptamers market is segmented into geographic atrophy, macular degeneration, pancreatic cancer, brain cancer, von willebrand diseases, chronic heart cancer and hemophilia A.

  • Pancreatic cancer segment led the aptamers segment led the market, capturing 31.8% of the market revenue share by 2035.
  • Geography atrophy segment is likely to grow at a higher CAGR, holding 25.8% of share during the forecast period by 2035.

Based on the route of administration, the aptamers market is segmented into intravitreal, intravenous, and subcutaneous.

  • Intravenous route dominates the aptamers market, capturing a major 49.5% of the share by 2035.
  • Intravitreal route drives the market, capturing 40.6% of the share by 2035, and is likely to grow during the forecast period.

Based on the Payment Model Employed, the aptamers market is segmented into upfront payment and milestone payment

  • Milestones payment segment capture 58% of the aptamers market revenue share by 2035.
  • The milestone payment segment is likely to grow at a higher CAGR 35.3% during the forecast period (2023-2035)

Based on geographical region, the aptamers market is segmented into North America, Europe, Asia-Pacific, and Rest of the World.

  • North America dominates the aptamers market, capturing the largest revenue share of 62.48% by 2035.
  • Europe captures 35.6% of the market share, which is anticipated to grow substantially in 2035.

Key Companies Profiled

The market report also covers the key companies profiles (listed below) that offer aptamers solutions:

  • Ajinomoto Bio-Pharma Services
  • BioSpring
  • CliniSciences
  • CMIC Group
  • Halo-Bio RNAi Therapeutics
  • LGC Biosearch Technologies
  • NeoNeuro
  • New England Biolabs
  • Nitto Denko Avecia
  • NOXXON Pharma
  • RIBOMIC
  • SomaLogic

You Can Ask a Question on the Aptamers Market by Clicking on the Given Link
https://www.rootsanalysis.com/reports/aptamers-therapeutics-technologies-and-services-market/ask-question.html

Don't Miss Out on Other Interesting Titles: 

Peptide Synthesis Service Market by Scale of Operation, Type of Synthesis Method Used, Company Size and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035

Pharmaceutical Contract Manufacturing Market by business segment, Type of API, type of FDF, Type of packaging form, scale of operation, end-users, and key geographical regions: Industry Trends and Global Forecasts (3rd Edition), 2021-2035

Spatial Genomics and Transcriptomics Market by Type of Solution, Type of Sample, End Users, Research Areas, and Key Geographical Regions: Industry Trends and Forecasts, 2022-2035

Gene Therapy Market by Type of Therapy, Type of Gene Delivery Method Used, Type of Vector Used, Target Therapeutic Areas, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts (5th Edition), 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma/biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists, and strategic investors for over a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research/consulting services dedicated to serving our clients in the best possible way.

Contact Us
Gaurav Chaudhary
Roots Analysis
+1 (415) 800 3415
Email: gaurav.chaudhary@rootsanalysis.com
Web: https://www.rootsanalysis.com/
Follow Us: LinkedIn| Twitter

Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.